CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法在血液系统恶性肿瘤中的局限性：聚焦抗原逃逸与 T 细胞功能障碍
英文原题：Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction.
查看英文原题
Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已彻底改变血液系统恶性肿瘤的治疗，但抗原逃逸和T细胞功能障碍仍限制其长期疗效。近期研究迅速阐明了抗原逃逸机制和T细胞内在功能障碍的分子基础，并揭示了当前CAR-T 治疗模式中的新脆弱环节。本综述讨论CAR-T 细胞疗法治疗血液系统恶性肿瘤的局限，尤其是抗原逃逸机制和T细胞功能障碍。值得注意的是，近年来，多靶点CAR-T 及工程化CAR-T 细胞在克服血液系统恶性肿瘤耐药和复发方面显示出良好的临床疗效。本文还讨论提高CAR-T 疗效的新兴策略，包括先进的CAR-T 细胞工程技术、发现新的治疗靶点以及开发多靶点CAR-T 细胞方案。
展开英文摘要原文
Chimeric antigen receptor T (CAR-T)-cell therapy has revolutionized the treatment of hematological malignancies, yet long-term efficacy remains constrained by antigen escape and T-cell dysfunction. Recent advances have rapidly elucidated the molecular underpinnings of antigen escape mechanisms and intrinsic T-cell dysfunction, revealing novel vulnerabilities in current CAR-T paradigms.
In this review, we discuss the limitations of CAR-T-cell therapy in hematological malignancies, particularly regarding antigen escape mechanisms and T-cell dysfunction. It is noteworthy that in recent years, multi-targeted CAR-T and engineered CAR-T cells have demonstrated promising clinical efficacy in overcoming drug resistance and relapse in hematological malignancies.
Here, we also discuss emerging approaches to enhance the efficacy of CAR-T-cell therapy, including advanced CAR-T-cell engineering techniques, the identification of novel therapeutic targets, and the development of multi-targeted CAR-T-cell strategies.
论文信息
- 作者
- Lin Y、Luo S、Wei J、Lin S、Wang D、Zhao X、Feng Z、Shen Y
- 单位
- Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Qishan Campus, Fujian Normal University, Fuzhou 350117, China.China
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2025 Oct 3
- 原文标识
- PubMed 41096934 · DOI 10.3390/ijms26199669
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →